Analyst Price Targets — HROW
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 13, 2026 12:43 pm | Steve Seedhouse | Cantor Fitzgerald | $88.00 | $28.79 | TheFly | Harrow price target lowered to $88 from $91 at Cantor Fitzgerald |
| March 18, 2026 4:00 pm | Thomas Shrader | BTIG | $63.00 | $34.68 | StreetInsider | BTIG Reiterates Buy Rating on Harrow Health (HROW) ahead of presentations |
| March 4, 2026 11:41 am | Yi Chen | H.C. Wainwright | $70.00 | $39.62 | StreetInsider | Harrow Health (HROW) PT Raised to $70 at H.C. Wainwright |
| November 11, 2025 7:51 pm | — | Cantor Fitzgerald | $94.00 | $38.74 | TheFly | Cantor Fitzgerald reiterates Overweight rating on Harrow, ups target to $94 |
| September 29, 2025 12:36 pm | Thomas Flaten | Lake Street | $70.00 | $47.10 | TheFly | Harrow price target raised to $70 from $42 at Lake Street |
| September 23, 2025 12:59 pm | Chase Knickerbocker | Craig-Hallum | $64.00 | $48.93 | TheFly | Harrow price target raised to $64 from $54 at Craig-Hallum |
| August 13, 2025 10:18 am | Yi Chen | H.C. Wainwright | $64.00 | $34.83 | TheFly | Harrow price target raised to $64 from $60 at H.C. Wainwright |
| July 11, 2025 12:00 pm | Steve Seedhouse | Cantor Fitzgerald | $76.00 | $34.93 | TheFly | Harrow initiated with an Overweight at Cantor Fitzgerald amid path to growth |
| October 18, 2024 6:10 am | Sahil Kazmi | B.Riley Financial | $73.00 | $56.41 | StreetInsider | Harrow Health (HROW) PT Raised to $73 at B.Riley |
| October 4, 2024 8:41 am | Brooks O'Neil | Lake Street | $55.00 | $49.75 | TheFly | Harrow price target raised to $55 from $45 at Lake Street |
Latest News for HROW
Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar
INCHEON, Korea--(BUSINESS WIRE)-- #Byooviz--Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for commercialization of BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTIS1 (ranibizumab), and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEA2 (aflibercept), upon full…
Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an FDA-approved VKC treatment for pediatric patients.
Harrow Inc. (NASDAQ:HROW) on Wednesday announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment for vernal keratoconjunctivitis (VKC), a serious allergic eye condition that primarily affects children.
NASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the re-launch of VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy indicated for the treatment of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HROW.
U.S. House Trading
No House trades found for HROW.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.